- Home
- BMRC vs ALMS Comparison
BMRC vs ALMS Comparison
Compare BMRC & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRC
- ALMS
- Stock Information
- Founded
- BMRC 1989
- ALMS 2021
- Country
- BMRC United States
- ALMS United States
- Employees
- BMRC N/A
- ALMS N/A
- Industry
- BMRC Major Banks
- ALMS
- Sector
- BMRC Finance
- ALMS
- Exchange
- BMRC Nasdaq
- ALMS NYSE
- Market Cap
- BMRC 361.9M
- ALMS 402.6M
- IPO Year
- BMRC N/A
- ALMS 2024
- Fundamental
- Price
- BMRC $25.39
- ALMS $3.28
- Analyst Decision
- BMRC Buy
- ALMS Strong Buy
- Analyst Count
- BMRC 4
- ALMS 7
- Target Price
- BMRC $25.50
- ALMS $24.50
- AVG Volume (30 Days)
- BMRC 137.8K
- ALMS 855.0K
- Earning Date
- BMRC 07-28-2025
- ALMS 08-12-2025
- Dividend Yield
- BMRC 3.96%
- ALMS N/A
- EPS Growth
- BMRC N/A
- ALMS N/A
- EPS
- BMRC N/A
- ALMS N/A
- Revenue
- BMRC $70,630,000.00
- ALMS $17,389,000.00
- Revenue This Year
- BMRC $69.47
- ALMS N/A
- Revenue Next Year
- BMRC $9.30
- ALMS N/A
- P/E Ratio
- BMRC N/A
- ALMS N/A
- Revenue Growth
- BMRC N/A
- ALMS N/A
- 52 Week Low
- BMRC $15.93
- ALMS $2.76
- 52 Week High
- BMRC $27.11
- ALMS $13.50
- Technical
- Relative Strength Index (RSI)
- BMRC 77.99
- ALMS N/A
- Support Level
- BMRC $22.54
- ALMS N/A
- Resistance Level
- BMRC $22.57
- ALMS N/A
- Average True Range (ATR)
- BMRC 0.85
- ALMS 0.00
- MACD
- BMRC 0.28
- ALMS 0.00
- Stochastic Oscillator
- BMRC 99.76
- ALMS 0.00
About BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.